Skip to main content

Transcode Therapeutics, Inc.

RNAZ
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001829635

No open-market purchases or sales by Transcode Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $208.1K in total; no superinvestor holds it.

13F holders, Q1 2026

Institutional positions in Transcode Therapeutics, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
8
+2 vs. Q4 2025
Shares held
30.9K
+27.0K (+695.5%) vs. Q4 2025
Total value
$265.7K
+$239.2K (+904.6%) vs. Q4 2025
New holders
4
2 more added
Sold out
2
1 more reduced

Compare with Q4 2025: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting RNAZ on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ1 2026: 8 institutions
Q1 2021: 0 institutionsQ2 2021: 0 institutionsQ3 2021: 17 institutionsQ4 2021: 16 institutionsQ1 2022: 13 institutionsQ2 2022: 13 institutionsQ3 2022: 13 institutionsQ4 2022: 18 institutionsQ1 2023: 11 institutionsQ2 2023: 5 institutionsQ3 2023: 11 institutionsQ4 2023: 13 institutionsQ1 2024: 7 institutionsQ2 2024: 15 institutionsQ3 2024: 10 institutionsQ4 2024: 5 institutionsQ1 2025: 19 institutionsQ2 2025: 9 institutionsQ3 2025: 8 institutionsQ4 2025: 6 institutionsQ1 2026: 8 institutionsQ2 2026: 8 institutions
Value heldQ1 2026: $265.7K
Q1 2021: $0Q2 2021: $0Q3 2021: $7.28MQ4 2021: $5.98MQ1 2022: $3.14MQ2 2022: $2.67MQ3 2022: $2.27MQ4 2022: $222.5KQ1 2023: $88.6KQ2 2023: $476.6KQ3 2023: $281.6KQ4 2023: $105.4KQ1 2024: $284.1KQ2 2024: $263.0KQ3 2024: $185.8KQ4 2024: $33.4KQ1 2025: $1.06MQ2 2025: $237.0KQ3 2025: $155.0KQ4 2025: $26.4KQ1 2026: $265.7KQ2 2026: $208.1K
Institutions holding RNAZ and their total value by quarter
QuarterHoldersValue
Q2 20268$208.1K
Q1 20268$265.7K
Q4 20256$26.4K
Q3 20258$155.0K
Q2 20259$237.0K
Q1 202519$1.06M
Q4 20245$33.4K
Q3 202410$185.8K
Q2 202415$263.0K
Q1 20247$284.1K
Q4 202313$105.4K
Q3 202311$281.6K
Q2 20235$476.6K
Q1 202311$88.6K
Q4 202218$222.5K
Q3 202213$2.27M
Q2 202213$2.67M
Q1 202213$3.14M
Q4 202116$5.98M
Q3 202117$7.28M
Q2 20210$0
Q1 20210$0

Institutions, Q1 2026

Shares, value and share of portfolio for each institution holding Transcode Therapeutics, Inc.; share changes are against Q4 2025.

Institutions holding RNAZ in Q1 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Geode Capital Management, LLC12,740$109.7K0.00%+12,740New
UBS Group AG8,295$71.4K0.00%+5,331+179.9%Added
Vanguard Capital Management LLC6,545$56.4K0.00%+6,545New
Vanguard Fiduciary Trust Co2,982$25.7K0.00%+2,982New
Tower Research Capital LLC (TRC)228$1.96K0.00%−659−74.3%Reduced
Wells Fargo & Company55$4740.00%+55New
SBI Securities Co., Ltd.12$1030.00%+2+20.0%Added
Royal Bank of Canada8$00.00%00.0%Unchanged
Bank of America Corp0$00.00%−8−100.0%Sold out
Advisor Group Holdings, Inc.0$00.00%−3−100.0%Sold out